NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
Show detailsBibliographic details: Goring SM, Levy AR, Ghement I, Kalsekar A, Eyawo O, L'italien GJ, Kasiske B. A network meta-analysis of efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients. Current Medical Research and Opinion 2014; 30(8): 1473-1487. [PubMed: 24628478]
Abstract
Belatacept is a first in-class co-stimulation blocker developed for primary maintenance immunosuppression following renal transplantation. The objective of this study was to estimate the efficacy of belatacept relative to tacrolimus and cyclosporine among adults receiving a single kidney transplant. A systematic review was conducted of randomized clinical trials (RCTs) published between January 1990 and December 2013 using EMBASE, MEDLINE, the Cochrane Central Register of Controlled Trials, and unpublished study reports from two belatacept RCTs. Bayesian network meta-analysis (NMA) methods were used to compare the efficacy measures, mortality, graft loss, acute rejection and glomerular filtration rate (GFR). Heterogeneity was quantified using statistical metrics and potential sources were evaluated using meta-regression and subgroup analysis. A total of 28 RCTs comparing tacrolimus with cyclosporine, and three comparing belatacept with cyclosporine, were identified. All three agents provided comparable graft and patient survival, despite a higher risk of acute rejection associated with belatacept and cyclosporine. Belatacept was associated with significant improvement in GFR versus cyclosporine. Compared with tacrolimus, this difference was clinically meaningful yet statistically non-significant. The probability of being the best treatment was highest for belatacept for graft survival (68%), patient survival (97%) and renal function (89%), and highest for tacrolimus for acute rejection (99%).Variability in donor, recipient, and trial characteristics was present in the included RCTs; however, minimal statistical heterogeneity was detected in the analysis of acute rejection, graft or patient survival, and none of the characteristics were found to be significantly associated with relative effect. Although the direction of effect of immunosuppressants on GFR was consistent across RCTs, precise estimation of its magnitude was limited by a small number of RCTs and heterogeneity in relative effect sizes. Clinicians often seek an alternative to CNIs due to their nephrotoxic effects. The results of this indirect comparison indicate that belatacept is an effective immunosuppressive agent in renal transplantation among adults.
- Review Belatacept for kidney transplant recipients.[Cochrane Database Syst Rev. 2014]Review Belatacept for kidney transplant recipients.Masson P, Henderson L, Chapman JR, Craig JC, Webster AC. Cochrane Database Syst Rev. 2014 Nov 24; 2014(11):CD010699. Epub 2014 Nov 24.
- Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.[Am J Kidney Dis. 2017]Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.Grinyó JM, Del Carmen Rial M, Alberu J, Steinberg SM, Manfro RC, Nainan G, Vincenti F, Jones-Burton C, Kamar N. Am J Kidney Dis. 2017 May; 69(5):587-594. Epub 2016 Nov 23.
- Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes.[Clin J Am Soc Nephrol. 2011]Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes.Rostaing L, Neumayer HH, Reyes-Acevedo R, Bresnahan B, Florman S, Vitko S, Heifets M, Xing J, Thomas D, Vincenti F. Clin J Am Soc Nephrol. 2011 Nov; 6(11):2696-704. Epub 2011 Sep 15.
- Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.[Am J Transplant. 2016]Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.Wen X, Casey MJ, Santos AH, Hartzema A, Womer KL. Am J Transplant. 2016 Nov; 16(11):3202-3211. Epub 2016 Jun 14.
- Review Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients.[Cochrane Database Syst Rev. 2005]Review Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients.Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Cochrane Database Syst Rev. 2005 Oct 19; (4):CD003961. Epub 2005 Oct 19.
- A network meta-analysis of efficacy of belatacept, cyclosporine and tacrolimus f...A network meta-analysis of efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews
Your browsing activity is empty.
Activity recording is turned off.
See more...